Navigation Links
Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy
Date:12/7/2009

Medroxyprogesterone wins out in comparison study

SUNDAY, Dec. 6 (HealthDay News) -- Hot flashes caused by androgen suppression therapy for prostate cancer are best controlled by the hormonal treatments cyproterone acetate and medroxyprogesterone acetate, according to a new study.

Androgen suppression is considered the gold standard treatment for advanced prostate cancer, but about 80 percent of patients undergoing the treatment experience hot flashes. A number of hormonal and non-hormonal drugs are used to treat the hot flashes, but no direct comparisons of the drugs have been made in clinical trials.

The new study included 311 prostate cancer patients in France undergoing androgen suppression therapy. To treat their hot flashes, they received either the non-hormonal drug venlafaxine (102 men), or one of two hormonal drugs -- cyproterone acetate (101 men) or medroxyprogesterone acetate (108 men). The patients were assessed at weeks four, eight and 12 and asked to complete a questionnaire about the frequency and severity of their hot flashes for the week before each assessment.

The researchers found that all three drugs reduced the occurrence of hot flashes, but the hormonal drugs were much more effective at reducing them over all time periods.

After receiving treatment for four weeks, 219 patients (nearly 71 percent) reported an improvement of at least 50 percent in their hot flash scores, and 70 patients (nearly 23 percent) said they no longer had hot flashes. By the fourth week, hot flash scores were reduced by 47.2 percent for the venlafaxine group, 83.7 percent for the medroxyprogesterone acetate group and 94.5 percent for the cyproterone acetate group.

Among men receiving gonadotrophin-releasing hormone analogue therapy for prostate cancer, cyproterone acetate and medroxyprogesterone acetate are more effective at 12 weeks for treating hot flashes, the researchers concluded. However, "as cyproterone is a recognized treatment in prostate cancer, and its use could interfere with hormone therapy, medroxyprogesterone should be the standard treatment," they wrote.

The study will be published online Dec. 7 in The Lancet Oncology.

More information

The American Urological Association has more about androgen suppression therapy for prostate cancer.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Dec. 6, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Dr. Rabin Introduces a Bioidentical Hormones Program Adaptable to Individual Body and Hormonal Needs
2. When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research
3. Attorneys Learn of the Association Between Traumatic Brain Injury, Hormonal Deficiencies, Depression, and Heart Attacks
4. Hormonal Therapies Offer Effective Solutions for Many Adult Women With Acne
5. Pregnancy-related hormonal changes linked to increased risk of restless legs syndrome
6. Non-Hormonal Therapies Aid Breast Cancer Patients
7. Inheritance of hormonal disorder marked by excessive insulin in daughters
8. Synovics Pharmaceuticals Announces Execution of Hormonal Manufacture and Supply Contract
9. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
10. Hormonal dietary supplements might promote prostate cancer progression
11. Hormonal Changes and Depression: What is the Connection?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us that ... Prevention (CDC), a stroke is the fourth leading cause of death in the United States; ... with almost a quarter of them in individuals under 65 years old. A stroke ...
(Date:4/28/2016)... ... 2016 , ... Point Source Audio® (PSA) , an ... today that the US Patent Office has approved its patent submission that covers ... design creates a lightweight and modular audio headset that has been said to ...
(Date:4/28/2016)... Cary, NC (PRWEB) , ... April 28, 2016 ... ... to announce it has partnered with Community Oncology Pharmacy Association (COPA) to develop ... elevate the practice of oncology by introducing an accreditation distinction. ACHC provides a ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... Pharmacy Discount Cards in the mail from USA Medical Prescription Assistance Program. They ... , Each mailed package will include a ready-to-use, state-themed card and, ...
(Date:4/28/2016)... ... April 28, 2016 , ... For the 10,000 Americans who turn ... an important part of overall well-being: mental health. Now, a new book—Staying Sharp For ... aging and “cognitive vitality,” which can include everything from honing your memory and managing ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- Research and Markets has announced the ... 2016-2020" report to their offering.      ... global plastic surgery products market is expected to grow ... , ,The growing adoption of laser in aesthetics is ... market. Lasers are used to treat a broad range ...
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... April 28, 2016 Dr. Vivek ... and Ste phen Schmidt ... a leading provider of cloud-based software solutions for life sciences, today ... to bring a wealth of insight to a growing business.  This ... George Phillips joined ArisGlobal in the position ...
Breaking Medicine Technology: